GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Day One Biopharmaceuticals Inc (NAS:DAWN) » Definitions » Interest Coverage

Day One Biopharmaceuticals (Day One Biopharmaceuticals) Interest Coverage : No Debt (1) (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Day One Biopharmaceuticals Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Day One Biopharmaceuticals's Operating Income for the three months ended in Dec. 2023 was $-59.52 Mil. Day One Biopharmaceuticals's Interest Expense for the three months ended in Dec. 2023 was $0.00 Mil. Day One Biopharmaceuticals has no debt. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Day One Biopharmaceuticals Inc has enough cash to cover all of its debt. Its financial situation is stable.

(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Day One Biopharmaceuticals's Interest Coverage or its related term are showing as below:


DAWN's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 137.02
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Day One Biopharmaceuticals Interest Coverage Historical Data

The historical data trend for Day One Biopharmaceuticals's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Day One Biopharmaceuticals Interest Coverage Chart

Day One Biopharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Interest Coverage
- - N/A N/A No Debt

Day One Biopharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A No Debt

Competitive Comparison of Day One Biopharmaceuticals's Interest Coverage

For the Biotechnology subindustry, Day One Biopharmaceuticals's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Day One Biopharmaceuticals's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Day One Biopharmaceuticals's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Day One Biopharmaceuticals's Interest Coverage falls into.



Day One Biopharmaceuticals Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Day One Biopharmaceuticals's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, Day One Biopharmaceuticals's Interest Expense was $0.00 Mil. Its Operating Income was $-206.06 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

Day One Biopharmaceuticals had no debt (1).

Day One Biopharmaceuticals's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Here, for the three months ended in Dec. 2023, Day One Biopharmaceuticals's Interest Expense was $0.00 Mil. Its Operating Income was $-59.52 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

Day One Biopharmaceuticals had no debt (1).

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Day One Biopharmaceuticals  (NAS:DAWN) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Day One Biopharmaceuticals Interest Coverage Related Terms

Thank you for viewing the detailed overview of Day One Biopharmaceuticals's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Day One Biopharmaceuticals (Day One Biopharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
2000 Sierra Point Parkway, Suite 501, Brisbane, CA, USA, 94005
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The lead product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.
Executives
York Charles N Ii officer: COO, CFO and Secretary 901 S. MOPAC EXPRESSWAY, BARTON OAKS PLAZA ONE, SUITE 250, AUSTIN TX 78746
Samuel C. Blackman officer: Chief Medical Officer 395 OYSTER POINT BLVD., SUITE 217, SOUTH SAN FRANCISCO CA 94080
Jeremy Bender director, officer: Chief Executive Officer 395 OYSTER POINT BLVD., SUITE 217, SOUTH SAN FRANCISCO CA 94080
Ai Day 1 Llc 10 percent owner 40 WEST 57TH STREET, 28TH FLOOR, NEW YORK NY 10019
Julie Papanek Grant director 2765 SAND HILL ROAD, MENLO PARK CA 94025
Canaan Xi L.p. 10 percent owner 2765 SAND HILL RD, MENLO PARK CA 94025
Garry A Nicholson director C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Atlas Venture Opportunity Fund Ii, L.p. 10 percent owner 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Michael Gladstone director 395 OYSTER POINT BLVD, SUITE 217, SOUTH SAN FRANCISCO CA 94080
Atlas Venture Fund Xi, L.p. 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Takeda Pharmaceutical Co Ltd 10 percent owner 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668
Takeda Pharmaceuticals U.s.a., Inc. 10 percent owner ONE TAKEDA PARKWAY, DEERFIELD IL 60015
Takeda Ventures, Inc. 10 percent owner 9625 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
J. Scott Garland director 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
John A. Josey director C/O PELOTON THERAPEUTICS, INC., 2330 INWOOD ROAD, SUITE 226, DALLAS TX 75235

Day One Biopharmaceuticals (Day One Biopharmaceuticals) Headlines

From GuruFocus

Day One Announces Pricing of Public Offering of Common Stock

By GlobeNewswire GlobeNewswire 06-07-2023

Insider Alert: An Insider Just Sold Day One Biopharmaceuticals Inc Shares

By GuruFocus Research GuruFocus Editor 01-25-2023

Day One to Present at the 41st Annual J.P. Morgan Healthcare Conference

By Value_Insider Value_Insider 12-20-2022

Day One Announces Proposed Public Offering of Common Stock

By sperokesalga sperokesalga 06-06-2023